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Abstract 21 
 22 
Utilisation of functionalized liposomes as the means of targeted delivery of therapeutics may 23 
enhance specific transport of biologically active drugs to target tissues, while avoiding or reducing 24 
undesired side-effects. In the present investigation, peptide-conjugated cationic liposomes were 25 
constructed with the aim of targeting integrins (i.e. vitronectin and/or fibronectin receptors) on 26 
activated endothelial cells. The peptide-conjugated liposomes induced only cytotoxicity at the 27 
highest concentration in non-activated or activated endothelial cells, as well as in co-culture of 28 
endothelial cells and macrophages. There was unaltered secretion of cytokines following exposure 29 
of peptide-conjugated liposomes to endothelial cells, indicating that the materials were not 30 
inflammogenic. Liposomes with a peptide targeting the fibronectin receptor (integrin α5β1) were 31 
more effective in targeting of activated endothelial cells, as compared to a liposome with a peptide 32 
that targeted both the fibronectin and vitronectin receptors, as well as liposomes with a control 33 
peptide. The liposome targeted to the fibronectin receptor also displayed uptake in endothelial cells 34 
in co-culture with activated macrophages. Therefore, this study demonstrates the feasibility of 35 
constructing a peptide-conjugated cationic liposome, which displays targeting to activated 36 
endothelial cells at concentrations that are not cytotoxic or inflammogenic to the cells.  37 
  38 
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Introduction 39 
Liposomes are artificial vesicles made of an aqueous core surrounded by a lipid bilayer [1]. These 40 
vesicles have been designed and utilised as delivery vehicles for drugs, genetic material and 41 
imaging agents for parental administration [2]. The encapsulation of the cargo into the liposomes 42 
can protect the drug against metabolic transformation, enable transport across biological barriers, 43 
and control the release in target tissues, hence the subsequent alleviation of side effects associated 44 
with drug. Due to their small size, charge and the possibility for modification and inclusion of 45 
targeting moieties, liposomes can be ideal candidates for improved targeting and delivery to the 46 
target tissue [3]. Indeed, liposomes can accommodate a wide range of specific adhesion molecules 47 
and polymers on their surface, which can aid adhesion to vascular cells [4-8]. Furthermore, it has 48 
been demonstrated that liposomes exhibit enhanced permeability and retention in certain areas of 49 
the vasculature, which suggests that it is possible to influence the distribution of liposomes in the 50 
cardiovascular system [9].  51 
Endothelial cells line all blood vessels and regulate the flow of nutrients, biologically active 52 
molecules and an array of leukocytes. This role of the endothelium is governed through membrane-53 
bound receptors, lipid transporting particles, hormones and proteins that govern cell-cell and cell-54 
matrix interactions [10]. Integrins (i.e. αv integrins) on the endothelial cells bind to extracellular 55 
matrix proteins and other adhesion receptors on neighbouring cells. The integrins on the surface of a 56 
cell will determine whether it can adhere to and/or survive in a particular microenvironment, 57 
therefore the matching of integrins and ligands play a key role in the regulation of the sprouting 58 
ability of endothelial cells during angiogenesis and localization of leukocytes to sites of tissue 59 
inflammation. The peptide sequences arginine-glycine-aspartic acid (RGD) and C16Y 60 
(DFKLFAVYIKYR) have been identified as ligands for interaction and binding of integrins αvβ3, 61 
αvβ5 and α5β1. The usefulness of these sequences has been exploited as drug delivering systems to 62 
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target specific cell types [11-14]. The challenge is to attach a short peptide to liposomes that 63 
specifically target the cell type in question for therapy. The integrin α5β1 (fibronectin receptor) and 64 
αvβ3 (vitronectin receptor) are typically expressed on endothelial cells, although the number of 65 
receptors depends on the type of endothelial cells. For instance, the fibronectin receptor is much 66 
more abundant on primary human umbilical vein endothelial cells (HUVECs) than the vitronectin 67 
receptor [15, 16]. The vitronectin receptor is abundantly expressed on angiogenic endothelial cells 68 
in remodelling and pathological tissues as compared to the expression in normal quiescent 69 
endothelial cells [17]. The vitronectin and fibronectin receptors are ubiquitous integrins, playing an 70 
important role in a diverse range of biologic processes including cell migration, tumour invasion, 71 
angiogenesis and immune responsiveness [18-21]. 72 
To date, very few studies have designed stable, novel peptide-conjugated liposomes for potential 73 
cardiovascular disease therapy (with negligible adverse immunogenic capacity as well as enhanced 74 
targeting ability). In the present investigation, we investigated the targeting and toxicity of cationic 75 
liposomes with functionalization to target integrins on activated endothelial cells. We assessed 76 
differences in targeting and toxicity in endothelial cells that were in normal state and after insults 77 
such as local inflammation and early atherosclerotic lesions: 1) quiescent endothelial cells, 2) 78 
endothelial cells activated by lipopolysaccharide (LPS), 3) activated cells with presence of immune 79 
cells (e.g. activated macrophages or foam cells). The co-culture model was utilized to mimic the 80 
inflammatory response when phagocytes (predominantly macrophages) increase adhesiveness to the 81 
endothelium, secrete inflammatory soluble proteins and produce reactive oxygen species. Activated 82 
macrophages engulf materials through binding to scavenger receptors. Thus, they may compete 83 
with endothelial cells with regards to uptake of peptide-modified liposomes. 84 
 85 
Materials and methods 86 
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Synthesis of unconjugated liposomes 87 
The lipids 1,2-dioleoyl-sn-glycero-3-phoshocholine (DOPC) (Avanti Polar Lipids Inc., Alabaster, 88 
AL, USA) and N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP) 89 
(Avanti Polar Lipids Inc., Alabaster, AL, USA) (molar ratio - 9:1) were dissolved in chloroform and 90 
thoroughly mixed in a glass vial. The solution was allowed to dry under vacuum for 2 hr in order 91 
for a lipid film to form on the glass and to ensure the complete removal of chloroform. The 92 
unconjugated liposomes were rehydrated carefully by the addition of phosphate buffered saline 93 
(PBS), for a final lipid concentration of 1 mg/ml. The mixture was incubated unstirred overnight at 94 
room temperature. The following day, the unconjugated liposomes were subjected to ten freeze-95 
thaw cycles to minimize multi-lamellarity by immersion in liquid nitrogen, followed by thawing in 96 
40ºC water bath. The liposomes were sequentially extruded through two stacked polycarbonate 97 
filters with pore sizes of 50 nm (Mini-extruder - Avanti Polar Lipids Inc., Alabaster, AL, USA), 98 
before being stored at 4ºC until use. 99 
 100 
Peptide design and synthesis 101 
The lipidated peptides for targeting integrins were assembled by solid-phase peptide synthesis 102 
(SPPS) using amino acids carrying an Nα-9-fluorenylmethyloxy carbonyl (Fmoc) protecting group 103 
(see Supplementary Information). The lipid chain was introduced by on-resin modification of a C-104 
terminal Lys (fig. 1). This Lys residue was incorporated with a allyloxycarbonyl (Alloc) side-chain 105 
protecting group, as Fmoc-Lys(Alloc)-OH). After assembly of the linear sequence, the Alloc 106 
protecting group was selectively removed, while the other protecting groups remained intact. The 107 
free Lys side-chain amine was acylated with palmitic acid to ensure optimal anchoring to the 108 
liposome surface. Next, the N-terminal Fmoc protecting group was removed and the N-terminal 109 
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amine tagged by amide bond formation with an ATTO465 fluorophore for in vitro fluorescent 110 
detection. Finally, the peptides were deprotected and released from the support.  111 
Peptides 2 and 3 were designed to target integrins αvβ3, αvβ5 and/or α5β1 on endothelial cells 112 
while peptide 1 was designed as randomized control sequence of amino acids (fig. 2). 113 
 114 
Preparation of the peptide-conjugated liposomes 115 
The three different peptides were added to the liposomes (1:5 weight ratio) in PBS and incubated 116 
unstirred overnight at room temperature in containers that were wrapped in tinfoil to avoid contract 117 
with light. Peptide-conjugated liposomes were then separated from unbound peptides using a PD-10 118 
desalting column according to manufacturer’s instructions (GE Healthcare, Brøndby, Denmark).  119 
 120 
Characterisation of unconjugated liposomes 121 
The hydrodynamic size distributions of the unconjugated liposomes dispersed in filtered water, PBS 122 
or complete cell culture medium was determined in the 10-50 µg/ml concentration range by 123 
Nanoparticle Tracking Analysis (Nanosight LM20, UK). The zeta potential of the liposomes in PBS 124 
were measured in a standard Malvern disposable folded capillary cells in a Zetasizer nano ZS with 125 
Malvern version 6.20 Software. A limulus amebocyte lysate (LAL) Pyrogent™ Plus assay (Lonza, 126 
Basel, Switzerland) was utilised to test for possible endotoxin contaminations of the liposomes. The 127 
kit was used according to the manufacturer’s guidelines. 128 
 129 
Cell culture and liposome treatment 130 
Primary HUVECs (Cell Applications, San Diego, CA, USA) were cultured in T75 flasks in 131 
endothelial cell growth medium (Cell Applications, San Diego, CA, USA). All incubations were 132 
carried out at 37°C and 5% CO2. The cells were utilised between passages 2-10 as they retain 133 
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morphologic and phenotypic characteristics of endothelial cells. THP-1 monocytes (American Type 134 
Culture Collection, Manassas, VA, USA) were cultured in Roswell Part Memorial Institute (RPMI) 135 
medium (Gibco, The Netherlands) supplemented with 10% foetal bovine serum (FBS) (Gibco, The 136 
Netherlands), 2 mM L-glutamine and 100 U/ml Penicillin/Streptomycin (Sigma, UK).  137 
The HUVECs were activated utilising 2 µg/ml of Escherichia coli LPS for 2 hr (serotype O26:B26, 138 
Sigma, UK). In the co-culture model, the HUVECs and THP-1 cells (4:1 ratio) were cultured in 139 
complete HUVEC medium supplemented with 10 ng/ml of phorbol 12-myristate 13-acetate (PMA) 140 
(Sigma, UK) 24 hr before the addition of LPS for 2 hr [22]. The cells were rinsed in PBS and 141 
subsequently treated with liposomes.  142 
The cell cultures were exposed to liposomes in a concentration range between 0.61 and 312.5 143 
µg/cm2 (equivalent to 2-1000 µg/ml).  144 
 145 
WST-1 cell viability assay 146 
The cells (all three different cultures - non-activated HUVECs, activated HUVECs and 147 
HUVECs/macrophage co-culture) were seeded in 96 well plates (104 cells per well in 100 µl of the 148 
cell culture medium) and incubated for 24 hr before they were exposed to the liposomes for 24 hr. 149 
The first 24 hr incubation period was used to avoid a seeding effect in the cells and the subsequent 150 
24 hr period is a standardized incubation for measurement of cytotoxicity with the WST-1 assay.  151 
Subsequent to treatment with peptide-conjugated liposomes, cell supernatants were collected and 152 
frozen at -80ºC and later used for soluble protein measurements. The plates were incubated with 10 153 
μl of the WST-1 cell proliferation reagent (Roche, USA) and 90 μl of fresh medium for 1 hr at 37ºC 154 
and 5% CO2. The supernatant was transferred to a fresh plate and the absorbance was measured by 155 
spectrophotometry at 450 nm (the supernatants transfer into fresh plates was carried out to reduce 156 
the potential interference with materials during the measurements).  157 
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 158 
Peptide-conjugated liposome-induced inflammatory response 159 
After exposure, the cell culture supernatants were collected and stored at -80ºC. The concentrations 160 
of interleukin (IL) 1β, IL6, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 161 
molecule-1 (VCAM-1), macrophage inflammatory protein-1α (MIP-1α), tumour necrosis factor-α 162 
(TNF-α) and granulocyte-colony stimulating factor (G-CSF) supernatants were determined with 163 
BDTM Cytometric Bead Array cytokine flex sets (bead based immunoassay; BD Biosciences, USA). 164 
Flow cytometry was utilised to discriminate between different bead populations based on size and 165 
fluorescence, according to the manufacturer’s instructions. The flex sets employ microparticles with 166 
distinct fluorescence intensities to detect soluble analytes (in this case cytokines/chemokines). In 167 
these experiments no positive control was included as we do not have a compound that increases the 168 
entire set of markers in both THP-1 cells and HUVECs. LPS exposure only increases the secretion 169 
of some cytokines and it is not the same concentration that produces a maximal response of 170 
different cytokines (unpublished observations). We have regarded the substantial difference in 171 
cytokine release between the non-activated HUVECs, activated HUVECs and co-culture as 172 
sufficient evidence of ability of the flex sets to determine concentration-response relationships in 173 
cultured cells.  174 
 175 
Liposome uptake - fluorescent microscopy 176 
The cells were seeded in 8 well microscopy chambers (Ibidi, Germany) (104 cells per well in 200 µl 177 
of the cell culture medium) and incubated for 24 hr at 37ºC and 5% CO2. The cells were exposed to 178 
PMA and/or LPS as previously described. The cells were exposed to the different peptide-179 
conjugated liposomes for 2 hr (7.8, 15.6 and 31.25 µg/cm2). Following liposome exposure, the cells 180 
were washed thoroughly with PBS and observed under a Leica AF6000 inverted wide-field 181 
9 
 
fluorescence microscope (Leica, Germany). The 2 hr exposure period for the microscopic uptake 182 
studies was based on preliminary data from time-course experiments utilising liposomes with 183 
similar physico-chemical characteristics (unpublished data) and previously published work with 184 
gold nanoparticles [23, 24]. The experiments were carried out on three different days; only 185 
representative images of 15.6 µg/cm2 are shown in the paper. 186 
 187 
Flow cytometric analysis of cell-associated fluorescence 188 
Following a 2 hr peptide-conjugated liposome treatment (15.6 µg/cm2), cell cultures (as described 189 
above) (106 cells per well) were washed three times and detached using trypsin/EDTA. The cells 190 
were centrifugated and re-suspended in 200 µl of PBS and analysed by flow cytometry using an 191 
Accuri C6 flow cytometer (Becton Dickinson, USA). The results are reported as the mean 192 
fluorescence from 104 cells, which were analysed in each flow cytometry analysis.  193 
 194 
Semi-quantification of cellular uptake 195 
The cells (all three different cultures) were seeded in 96 well plates (104 cells per well in 100 µl of 196 
the cell culture medium) and incubated for 24 hr at 37ºC and 5% CO2. The following day the cells 197 
were exposed to the different peptide-conjugated liposomes (15.6 µg/cm2) for 2 or 6 hr at 37ºC and 198 
5% CO2. The supernatant from each well was transferred to opaque plates and the fluorescence was 199 
measured (Fluoroskan Ascent FL Microplate Fluorometer and Luminometer, Thermo Scientific, 200 
USA).  201 
 202 
Statistical analysis 203 
All data are expressed as mean ± standard error of the mean (SEM). For statistical analysis, the 204 
experimental results were compared to their corresponding control values using full-factorial 205 
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ANOVA with Tukey’s multiple comparison. All statistical analysis was carried out utilizing 206 
Minitab 17. All experiments were repeated independently on at least three separate occasions. 207 
 208 
Results 209 
Liposome characterisation 210 
The particle sizes of the unconjugated liposomes were determined in filtered water, PBS and the 211 
HUVEC complete medium (table 1). Representative examples of the particle size distribution are 212 
provided in supplementary figure 1. The data demonstrated that there was only a slight tendency for 213 
the unconjugated liposomes to agglomerate over a 3 month period. In keeping with previous 214 
observations on other types of particles [25, 26], particle sizes were larger in HUVEC medium as 215 
compared to water or PBS. The HUVEC medium contains serum proteins of different sizes, which 216 
may cause agglomeration of liposomes or affect the readings in the Nanosight analysis.  217 
No endotoxin contamination (≤ 0.25 EU/ml) was detected for the peptide-conjugated liposomes.  218 
 219 
Cytotoxicity  220 
The peptide-conjugated liposomes induced cytotoxicity in a log-linear manner (fig. 3). The 221 
activated HUVECs displayed the lowest level of cytotoxicity, followed by non-activated HUVECs 222 
and co-cultures of HUVECs and macrophages. Nevertheless, there was no difference in the 223 
cytotoxicity profile between the different peptide-conjugated liposomes in any of the cell culture 224 
models at the concentrations investigated. For all other experiments than the WST-1 assay we used 225 
a maximal concentration close to cytotoxicity (cytokine secretion; 40 µg/cm2) or a sub-cytotoxic 226 
concentration (attachment/uptake; 15.6 µg/cm2)  227 
 228 
Inflammatory response 229 
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The concentration of MIP-1α, TNF-α, IL6, ICAM-1, VCAM-1, G-CSF and IL1-β were measured in 230 
the supernatants of cell cultures after 24 hr exposure to the liposomes (figs. 4 and 5). A 24 h 231 
exposure for assessment of the inflammation response was used as earlier time points, i.e. 2 and 6 232 
hr, might be too early for production and detection of cytokine and cell adhesion molecule secretion 233 
in the cell culture supernatant. In general, the secretion of inflammatory cytokines by non-activated 234 
HUVECs was relatively low. These cytokines were slightly increased in the supernatant of activated 235 
HUVECs (3-4 fold as compared to non-activated HUVECs). The co-cultures of HUVECs and 236 
macrophages had substantially higher concentrations of cytokines in the supernatants (up to 100-237 
fold), which are most likely originating from the macrophages. Importantly, the exposure to 238 
peptide-conjugated liposomes did not affect the secretion of cytokines in any of the cell culture 239 
models. 240 
 241 
Targeting and uptake of liposomes by HUVECs  242 
The targeting and internalization of the peptide-conjugated liposomes were assessed by 243 
combination of flow cytometry, fluorescent microscopy and fluorometric determination of the 244 
concentration of peptide-liposome conjugates in the supernatant in the three cell cultures. Figure 6 245 
depicts a semi-quantitative analysis of the concentration of conjugates that remained in the 246 
supernatant of the cell cultures after 2 or 6 hr exposure. This particular experimental setup cannot 247 
distinguish between peptide-conjugated liposomes that have been internalized or merely attached to 248 
the cell membrane. Nevertheless, there was higher attachment or uptake of peptide-conjugated 249 
liposomes at 6 hr as compared to 2 hr. Liposomes with peptide 2 displayed the highest level of 250 
attachment or uptake in activated HUVECs. Liposomes with peptide 2 or 3 also displayed higher 251 
attachment or uptake in the co-culture as compared to liposomes with peptide 1.  252 
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In an attempt to distinguish between attachment and uptake of liposomes in HUVECs and 253 
macrophages, we used fluorescence microscopy (fig. 7). However, it was inherently difficult to 254 
obtain clear two-dimensional images of co-cultures because HUVECs are flat on the surface of the 255 
microscope slide, whereas macrophages are round cells that attach on top of the endothelial cells. 256 
The fluorescent microscopy showed presence of liposomes (red colour in the images) in the 257 
perinuclear area of HUVECs after 2 hr exposure, indicating internalization of all types of peptide-258 
conjugated liposomes. Due to the quality of the images it was not possible to quantitatively assess 259 
the uptake of peptide-conjugated liposomes. In the co-cultures, both HUVECs and macrophages 260 
displayed uptake of peptide-conjugated liposomes, but it was not possible to measure differences in 261 
the uptake of liposomes with different peptides or cell types.  262 
A direct quantitative comparison of differences in the adhesion/uptake of peptide-conjugated 263 
liposomes was carried out by flow cytometry (fig. 8). This showed that the liposome with peptide 2 264 
had higher fluorescent signal after 2 hr exposure as compared to liposomes with peptide 1 or 3. It 265 
should be noted that the flow cytometry method in this study cannot distinguish between 266 
fluorescence signals from outside and inside cells. However, the collective experimental evidence 267 
from the fluorometric determination of peptide-liposome conjugates in the supernatant (fig. 6), 268 
fluorescence microscopy (fig. 7) and flow cytometry (fig. 8) indicates uptake of peptide-conjugated 269 
liposomes in activated HUVECs and THP-1 cells. 270 
 271 
Discussion 272 
The results from this study show that HUVECs had either a higher uptake of liposomes with 273 
peptide 2 as compared to liposomes with peptide 1 and 3, or a faster uptake within the exposure 274 
period. Moreover, the targeting of peptide 2 was also observed in co-cultures of HUVECs and 275 
macrophages, indicating a somewhat robust delivery of the peptide-conjugated liposomes to 276 
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HUVECs in a pro-inflammatory environment where scavenging by activated macrophages may 277 
lead to inefficient targeting. The targeting of HUVECs with these peptide-conjugated cationic 278 
liposomes did not cause cytotoxicity or inflammation. 279 
The present study allows for a direct comparison between two peptide-conjugated liposomes for 280 
targeting integrins under the exact same experimental conditions. It has been shown that HUVECs 281 
have a higher expression of integrin α5β1 than αvβ3 and αvβ5, whereas other types of endothelial 282 
cells have a different expression of integrins [15, 16]. Both peptide 2 and 3 target the integrin αvβ5, 283 
indicating the difference between these peptides is mainly that peptide 3 has a competing binding to 284 
integrin αvβ3 (i.e. vitronectin receptor) and α5β1 (i.e. fibronectin receptor). The difference between 285 
peptide 2 and 3 suggests that the internationalization of peptide-conjugated liposomes via binding to 286 
the fibronectin receptor could be more effective than the vitronectin receptor. It is also possible that 287 
the affinity for binding to the specific receptors is higher for peptide 2 in comparison to peptide 3. It 288 
should be noted that the peptides were lipidated for anchorage to liposomes. This type of 289 
hydrophobic association is less strong or stable than covalent bonding. However, detachment of the 290 
lipidated peptides from liposomes is chemically unfavourable in the aqueous environment of cell 291 
cultures.   292 
During an inflammatory response, circulating human leukocytes are able to leave the blood and 293 
enter the site of injury by migration through endothelial and sub-endothelial matrices. The integrins 294 
on endothelial cells are heavily involved in this migration process together with cell adhesion 295 
molecules PECAM (CD31), ICAM-1, VCAM-1 and selectins [27]. Our results indicated enhanced 296 
binding/uptake of peptide-conjugated liposomes in activated HUVECs. It has been described that 297 
TNF-α activated HUVECs had increased uptake of anti-VCAM-Fab’-conjugated liposomes as 298 
compared to non-activated cells [28]. Other studies on IL-1α activated HUVECs also showed 299 
enhanced uptake of liposomes that were coupled with antibodies against cell adhesion molecules on 300 
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endothelial cells [29, 30]. Activated macrophages engulf materials through binding to scavenger 301 
receptors. Thus, activated macrophages may compete with endothelial cells with regards to uptake 302 
of peptide-modified liposomes. In addition, there was uptake of liposomes with peptide 2 in 303 
HUVECs in the co-culture with activated macrophages. Liposomes with peptide 3 only showed 304 
uptake in the co-culture, indicating that it was mainly engulfment by macrophages. These 305 
reflections stem from observations in cultured cells, which is test system utilised in this study.. One 306 
of the on-going issues in nanomedicine is the effect of protein corona [31]. In this study the cell 307 
culture medium contain serum which is required for cell survival and growth.. Thus, the peptide-308 
conjugated liposomes were most likely coated with a protein corona. Interestingly, it has been 309 
shown that a protein corona favours the internalization of liposomes by macrophages and tumour 310 
cells. [32]. Circulating nanoparticles in the blood stream are most likely coated with a protein 311 
corona, but selective targeting has been shown for cell adhesion molecule-conjugated liposomes 312 
that accumulated in the target tissue in a rat experimental model of myocardial infarction [33].        313 
It has been previously demonstrated that administration of cationic liposomes may lead to activation 314 
of the innate immune system typified by the instigation of the complement system and strong 315 
myeloid inflammatory cell response [34, 35]. Moreover, at high dosage in vivo, cationic micelles 316 
have been demonstrated to cause inflammatory gene expression in lung, spleen and the liver, 317 
although there was no sign of toxicity with respect to routine pathology, histology and clinical 318 
chemistry end-points [36]. This cationic charge has also been shown to be associated with increased 319 
cellular toxicity [37, 38]. There is strong evidence that exposure to some types of carbon-based and 320 
metaloxide nanomaterials can increase the expression of ICAM-1 and VCAM-1 on the cell 321 
membrane of HUVECs [39-41]. This activation can lead to attachment between HUVECs and 322 
macrophages; the latter can be stimulated to accumulate lipids in the presence of carbon-based 323 
nanomaterials [42-44]. In this study a comprehensive investigation of potential adverse effects 324 
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following exposure of HUVECs and macrophages showed that the peptide-conjugated liposomes 325 
did not induce secretion of cell adhesion proteins (i.e. ICAM-1 and VCAM-1) or inflammatory 326 
response after 24 hr exposure at concentrations where adhesion/uptake to HUVECs were observed 327 
after 2 and 6 hr. However, it should also be emphasized that endothelial cells may not receive the 328 
highest exposure in vivo because large quantities of intravenously administrated particles 329 
accumulate in the liver [45].  330 
In summary, the data here demonstrated liposomes modified with peptide 2 to be a promising 331 
targeting candidate for improved specific delivery to activated endothelial cells on the lumen-side 332 
of atherosclerotic plaques in the arterial tree. Liposomes with peptide 2 have potential for delivery 333 
of a payload of therapeutic and/or imaging agents to application site while sparing or at least 334 
minimising exposure of normal healthy tissues. 335 
Despite being positively charged, the peptide-conjugated liposomes had negligible adverse 336 
immunogenic capacity and low-level of cytotoxicity to activated HUVECs and macrophages. 337 
 338 
Acknowledgements  339 
This work was supported by Lundbeck Foundation Center for Biomembranes in Nanomedicine 340 
(grant no: 0602-02331B), Danish Council of Independent Research (Medical Sciences, grant no. 341 
12-126262) and Villum Fonden (Center for Biomolecular Nanoscale Engineering). The authors 342 
declare no conflicts of interest. 343 
  344 
16 
 
References  345 
 346 
1.  Narayanaswamy R, Wang T, Torchilin VP. Improving peptide applications using 347 
nanotechnology. Curr Topics Med Chem 2016; 16: 253-270.  348 
 349 
2.  Li F, Jin L, He L, Deng Y, He NY. Nanoparticles applied for therapy and diagnosis in 350 
common diseases. Sci Adv Materials 2015; 7: 2103-2122.  351 
 352 
3.  Scott RC, Crabbe D, Krynska B, Ansari R, Kiani MF. Aiming for the heart: targeted 353 
delivery of drugs to diseased cardiac tissue. Expert Opinion on Drug Delivery 2008; 5: 459-354 
470.  355 
 356 
4. Bowey K., Tanguay JF, Tabrizian M. Liposome technology for cardiovascular disease 357 
treatment and diagnosis. Expert Opinion in Drug Delivery 2012; 9: 249-265.  358 
 359 
5.  Hosta-Rigau L, Schattling P, Teo BM, Lynge ME, Stadler B. Recent progress of liposomes 360 
in nanomedicine. J Materials Chem B 2014; 2: 6686-6691.  361 
 362 
6.  Xu LQ, Yu H, Yin SP, Zhang RX, Zhou YD, Li J. Liposome-based delivery systems for 363 
ginsenoside Rh2: in vitro and in vivo comparisons. J Nanopart Res 2015; 10: 415. 364 
 365 
7.  Zhang ZP, Mei L, Feng SS. Paclitaxel drug delivery systems. Expert Opinion on Research 366 
delivery 2013; 10: 325-340.  367 
 368 
8.  Lestini BJ, Sagnella SM, Xu Z, Shive MS, Richter NJ, Jayaseharan J, Case AJ, Kotte-369 
Marchant K, Anderson JM, Marchant RE. Surface modification of liposomes for selective 370 
cell targeting in cardiovascular drug delivery. Journal of Controlled Release 2002; 78: 235-371 
247.  372 
 373 
9. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Reviews 374 
Drug Discovery 2005; 4: 145-160.  375 
 376 
10. Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a 377 
targeted anti-VEGF for ocular vascular disease. Nature Reviews Drug Discovery 2006; 5: 378 
123-132.  379 
 380 
11. Farjo KM, Ma JX. The potential of nanomedicine therapies to treat neovascular disease in 381 
the retina. Journal of Angiogenesis Research 2010; 2: 21.  382 
 383 
12.  Gilad Y, Noy E, Senderowitz H, Albeck A, Firer MA, Gellerman G. Synthesis, biological 384 
studies and molecular dynamics of new anticancer RGD-based peptide conjugates for 385 
targeted drug delivery. Bioorganic and Medicinal Chemistry 2016; 24: 294-303.  386 
 387 
13. Hamano N, Negishi Y, Fujisawa A, Manandhar M, Sato H, Katagiri F, Nomizu M, Aramaki 388 
Y. Modification of the C16Y peptide on nanoparticles is an effective approach to target 389 
endothelial and cancer cells via the integrin receptor. Int J Pharmaceutics 2012; 428: 114-390 
117.  391 
 392 
17 
 
14. Mekuria SL, Debele TA, Chou HY, Tsia HC. IL-6 antibody and RGD peptide conjugated 393 
Poly(amidoamine) dendrimer for targeted drug delivery of HeLa cells. The Journal of 394 
Physical Chemistry B 2016; 120: 123-130.  395 
 396 
15. Short SM, Talbott GA, Juliano RL. Integrin-mediated signaling events in human endothelial 397 
cells. Mol Biol Cell 1998; 9: 1969-1980. 398 
 399 
16. Baranska P, Jerczynska H, Pawlowska Z, Koziolkiewicz W, Cierniewski C. Expression of 400 
integrins and adhesive properties of human endothelial cell line EA.hy 926. Cancer 401 
Genomics Proteomics 2005; 2: 265-270. 402 
 403 
17. Weis SM, Cheresh DA. αv integrins in angiogenesis and cancer. Cold Spring Harbour 404 
Perspectives in Medicine 2011; 1: a006478.  405 
 406 
18. Caccavari F, Valdembri D, Sandri C, Bussolino F, Serini G. Integrin signaling and lung 407 
cancer. Cell Adhesion and Migration 2010; 4: 124-129.  408 
 409 
19. Li R, Luo M, Ren M, Chen N, Xia J, Deng X, Zeng M, Yan K, Luo T, Wu J. Vitronectin 410 
regulation of vascular endothelial growth factor-mediated angiogenesis. Journal of Vascular 411 
Research 2014; 51: 110-117.  412 
 413 
20. Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE. The laminin 414 
binding integrin α6β1 in prostate cancer perineural invasion. Journal of Cellular Physiology 415 
2010; 224: 283-288.  416 
 417 
21. Veevers-Lowe J, Ball SG, Shuttleworth A, Kielty CM. Mesenchymal stem cell migration is 418 
regulated by fibronectin through α5β1-integrin-mediated activation of PDGFR-β and 419 
potentiation of growth factor signals. Journal of Cell Science 2011; 124: 1288-1300.  420 
 421 
22. Shi Q, Wang J, Wang XL, VandeBerg JL. Comparative analysis of vascular endothelial cell 422 
activation by TNF-alpha and LPS in humans and baboons. Cell Biochemistry and 423 
Biophysics 2004; 40: 289-303.  424 
 425 
23. Klingberg H, Loft S, Oddershede LB, Møller P. The influence of flow, shear stress and 426 
adhesion molecule targeting on gold nanoparticle uptake in human endothelial cells. 427 
Nanoscale 2015; 7: 11409-11419.  428 
 429 
24. Klingberg H, Oddershede LB, Loeschner K, Larsen EH, Loft S, Møller P. Uptake of gold 430 
nanoparticles in primary human endothelial cells. Toxicol Res 2015; 4: 655-666.  431 
 432 
25. Hemmingsen JG, Møller P, Nojgaard JK, Roursgaard M, Loft S. Oxidative stress, 433 
genotoxicity, and vascular cell adhesion molecule expression in cells exposed to particulate 434 
matter from combustion of conventional diesel and methyl ester biodiesel blends. Environ 435 
Sci Technol 2011; 45: 8545-8551.  436 
 437 
 438 
 439 
18 
 
26. Frikke-Schmidt H, Roursgaard M, Lykkesfeldt J, Loft S, Nøjgaard JK, Møller P. Effect of 440 
vitamin C and iron chelation on diesel exhaust particle and carbon black induced oxidative 441 
damage and cell adhesion molecule expression in human endothelial cells. Toxicol Lett 442 
2011; 203: 181-189. 443 
 444 
27. Seguin J, Nicolazzi C, Mignet N, Scherman D, Chabot GG. Vascular density and 445 
endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours. 446 
Tumour Biology 2012; 33: 1709-1717.  447 
 448 
28. Kang DI, Lee S, Lee JT, Sung BJ, Yoon JY, Kim JK, Chung J, Lim SJ. Preparation and in 449 
vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the 450 
poorly water-soluble drug celecoxib. J Microencapsul. 2011; 28: 220-7. 451 
 452 
29. Gunawan RC, Auguste DT. The role of antibody synergy and membrane fluidity in the 453 
vascular targeting of immunoliposomes. Biomaterials. 2010; 31: 900-7. 454 
 455 
30. Gunawan RC, Auguste DT. Immunoliposomes that target endothelium in vitro are 456 
dependent on lipid raft formation. Mol Pharm. 2010; 7: 1569-75. 457 
 458 
31. Caracciolo, G. Liposome–protein corona in a physiological environment: Challenges and 459 
opportunities for targeted delivery of nanomedicines. Nanomedicine: Nanotechnology, 460 
Biology, and Medicine. 2015; 11; 543–557. 461 
 462 
32. Corbo C, Molinaro R, Taraballi F, Toledano Furman NE, Sherman MB, Parodi A, Salvatore 463 
F, Tasciotti E. Effects of the protein corona on liposome-liposome and liposome-cell 464 
interactions. Int J Nanomedicine. 2016; 11: 3049-63. 465 
 466 
33. Scott RC, Wang B, Nallamothu R, Pattillo CB, Perez-Liz G, Issekutz A, Del Valle L, Wood 467 
GC, Kiani MF. Targeted delivery of antibody conjugated liposomal drug carriers to rat 468 
myocardial infarction. Biotechnol Bioeng. 2007; 96: 795-802. 469 
 470 
34. Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and 471 
challenges in drug delivery. Expert Opinions in Drug Delivery 2012; 9: 497-508.  472 
 473 
35. Bozzuto G, Molinar A. Liposomes as nanomedical devices. International Journal of 474 
Nanomedicine 2015; 10: 975-999.  475 
 476 
36. Knudsen KB, Northeved H, Kumar PE, Permin A, Gjetting T, Andersen TL, Larsen S, 477 
Wegener KM, Lykkesfeldt J, Jantzen K, Loft S, Møller P, Roursgaard M. In vivo toxicity of 478 
catotonic micelles and liposomes. Nanomedicine 2015; 11: 467-477.  479 
 480 
37. Iwaoka S, Nakamura T, Takano S, Tsuchiya S, Aramaki Y. Cationic liposomes induce 481 
apoptosis through p38 MAP kinase-caspase-8 Bid pathway in macrophage-like RAW264.7 482 
cells. Journal of Leukocyte Biology 2006; 79: 184-191.  483 
 484 
38. Lv H, Zhang S, Wang S, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in 485 
gene delivery. Journal of Controlled Release 2006; 114: 100-109.  486 
 487 
19 
 
39. Mikkelsen L, Jensen KA, Koponen IK, Saber AT, Wallin H, Loft S, Vogel U, Møller P. 488 
Cytotoxicity, oxidative stress and expression of adhesion molecules in human umbilical vein 489 
endothelial cells exposed to dust from paints with or without nanoparticles. Nanotoxicology 490 
2013; 7: 117-134.  491 
 492 
40. Vesterdal LK, Mikkelsen L, Folkmann JK, Sheykhzade M, Cao Y, Roursgaard M, Loft S, 493 
Møller P. Carbon black nanoparticles and vascular dysfunction in cultured endothelial cells 494 
and artery segments. Toxicol Lett 2012; 214: 19-26.  495 
 496 
41. Forchhammer L, Loft S, Roursgaard M, Cao Y, Riddervold IS, Sigsgaard T, Møller P. 497 
Expression of adhesion molecules, monocyte interactions and oxidative stress in human 498 
endothelial cells exposed to wood smoke and diesel exhaust particulate matter. Toxicol Lett 499 
2012; 209: 121-128.  500 
 501 
42. Cao Y, Jacobsen NR, Danielsen PH, Lenz AG, Stoeger T, Loft S, Wallin H, Roursgaard M, 502 
Mikkelsen L, Møller P. Vascular effects of multi-walled carbon nanotubes in dyslipidemic 503 
ApoE-/- mice and cultured endothelial cells. Toxicol Sci 2014; 138: 104-116. 504 
 505 
43. Cao Y, Roursgaard M, Danielsen PH, Møller P, Loft S. Carbon black nanoparticles promote 506 
endothelial activation and lipid accumulation in macrophages independently of intracellular 507 
ROS production. PLoS One 2014; 9: e106711.  508 
 509 
44. Cao Y, Roursgaard M, Jacobsen NR, Møller P, Loft S. Monocyte adhesion induced by 510 
multi-walled carbon nanotubes and palmitic acid in endothelial cells and alveolar-511 
endothelial co-cultures. Nanotoxicology 2016; 10: 235-244.  512 
 513 
45. Kermanizadeh A, Balharry D, Wallin H, Loft S, Møller P. Nanomaterial translocation - the 514 
biokinetics, tissue accumulation, toxicity and fate of materials in secondary organs - a 515 
review. Critical Reviews in Toxicology 2015; 45: 837-872.  516 
 517 
  518 
20 
 
Legends to figures 519 
 520 
Fig 1. Schematic representation of the applied synthesis strategy for the selected peptides: 1. Fmoc 521 
deprotection of the resin followed by SPPS. 2. Selective Alloc deprotection. 3. Lipidation of the Lys 522 
residue via amide coupling 4. Fmoc deprotection of the N-terminal. 5. Fluorescent tagging of the N-523 
terminal by amide coupling of ATTO465. 6. Deprotection and release of the final peptide product. 524 
 525 
Fig 2. The peptides utilised for targeting of activated endothelial cells. The regions important for 526 
the targeting and recognition of receptors on the cells are highlighted in red (DFKLFAVYIKYR for 527 
peptide 2 and RGD for peptide 3). Peptide 1 contains a scrambled sequence of amino acids without 528 
specific targeting to receptors on endothelial cells. 529 
 530 
Fig 3. Cytotoxicity of peptide-conjugated liposomes in non-activated HUVECs (a), activated 531 
HUVECs (b) or co-cultures of HUVECs and macrophages (c). The cells were exposed to cell 532 
medium (C) or peptide-conjugated liposomes for 24 hr. The graphs show results of liposomes with 533 
peptide 1 (blue, diamonds), 2 (red, squares) or 3 (green, triangles). The cytotoxicity measured via 534 
WST-1 assay. The values depict the mean ± SEM (n=3). 535 
 536 
Fig 4. Cytokine secretion following exposure to peptide-conjugated liposomes. The cells were 537 
exposed to cell medium as the negative control (Cont) or increasing concentrations of the peptide-538 
conjugated liposomes for 24 hr. The bars show results of liposomes with peptide 1 (blue), 2 (red) or 539 
3 (green). Missing bars are due to undetectable concentrations of cytokines. The values represent 540 
the mean ± SEM (n=3).  541 
 542 
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Fig 5. Secretion of ICAM-1 and VCAM-1 following exposure to peptide-conjugated liposomes. 543 
The cells were exposed to cell medium as the negative control (Cont) or increasing concentrations 544 
of the peptide-conjugated liposomes for 24 hr. The bars show results of liposomes with peptide 1 545 
(blue), 2 (red) or 3 (green). Missing bars are due to undetectable concentrations of cell adhesion 546 
molecules. The values represent the mean ± SEM (n=3). 547 
 548 
Fig 6. Uptake of peptide-conjugated liposomes by non-activated HUVECs, activated HUVECs and 549 
a co-culture of macrophages and HUVECs. The cells were exposed to (15.6 µg/cm2) of the peptide-550 
modified liposomes for 2 and 6 hr before the supernatant was removed, transferred to a fresh plate 551 
and fluorescence measured. For the control, the peptide-conjugated liposomes were incubated in 552 
empty wells before the above procedure was repeated. The percentage is the ration between  553 
fluorescence in the cell culture supernatant and fluorescence in the same volume of peptide-554 
conjugated liposome suspension without cells. The values represent the mean ± SEM (n=3) with 555 
significance indicated by *P<0.05 and **P<0.005 as compared to the liposomes modified with 556 
peptide 1 at the particular time-point. 557 
 558 
Fig 7. Fluorescent microscopy images of liposome uptake following 2 hr exposure to liposomes 559 
with peptide 1 (a, b), 2 (c, d) or 3 (e, f) (15.6 µg/cm2) to activated HUVECs (a, c, e) or co-culture of 560 
macrophages and HUVECs (b, d, f) (scale bar - 25 µm). Red spots (i.e. liposomes) can be seen in 561 
the perinuclear region of HUVECs, whereas it is not possible to discern differences in the uptake of 562 
different liposomes. Macrophages are visible on top of the HUVECs. Uptake of peptide-conjugated 563 
liposomes in macrophages is difficult to see in these images because they are focussed on HUVECs, 564 
which gives the round macrophages a bright light from the curved cell membrane. 565 
 566 
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Fig 8. Flow cytometric analysis of cell-associated fluorescence. Activated HUVECs were incubated 567 
with 15.6 µg/cm2 of liposomes with peptide 1 (black), 2 (red) or 3 (blue) for 2 hr. The values 568 
represent mean fluorescence from 10000 cells per treatment ± SEM (n=3), significance indicated by 569 
* = p<0.05 as compared to the liposomes modified with peptide 1. The insert shows an example of 570 
the flow cytometry analysis with the number of cells (y-axis) as the function of fluorescence in the 571 
cell (x-axis). A total of 104 cells have been analysed for each peptide-conjugated liposome.  572 
23 
 
Table 1. Particle size of unconjugated liposomes freshly prepared (measured within 2 hr of 573 
extrusion) or after 3 months incubation at 4°C after the extrusion step.  574 
 Liposome size of fresh samples Liposome size after 3 months 
Mean (nm) Mode (nm) Zeta 
potential 
(mV) 
Mean (nm) Mode (nm) 
Filtered water 73.7 ± 11.4 
(3) 
55.7 ± 7 (3) ND 95.6 ± 20.7 (3) 74.6 ± 18.6 (3) 
PBS 117.3 ± 16.7 
(6) 
107.1 ± 21.8 
(6) 
21.9 (1) 133.7 ± 31.4 
(3) 
128.4 ± 21.7 (3) 
Complete 
HUVEC 
medium 
204.6 ± 37.4 
(6) 
203 ± 41.2 
(6) 
ND 254.1 ± 
59.1(3) 
216.6 ± 23.5 (3) 
 The Nanosight analysis measured particle sizes in suspensions in the range between 10 and 1000 575 
nm. The “mean” is the average particle size of the suspension, whereas the “mode” is the size of the 576 
most abundant particle size. The results are mean and SEM (number of independent experiments). 577 
The Zeta potential is the charge of the particles. ND: not determined. 578 
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